The new treatment offers a median overall survival of 29.3 months for eligible AML patients and 10.3 months for those with intrahepatic cholangiocarcinoma, according to clinical data cited by the comp ...

Servier India has received approval for Vorasidenib (Voranigo), adding a second rare-cancer treatment to its portfolio in the ...

Bile duct cancer, or cholangiocarcinoma, is a malignant tumour of either the bile ducts within the liver (intrahepatic), or those leading from the liver to the small intestine (extrahepatic). It is a ...